Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) Enterprise Value (2018 - 2025)

Historic Enterprise Value for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to -$35.7 million.

  • Exagen's Enterprise Value fell 6201.5% to -$35.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.7 million, marking a year-over-year decrease of 6201.5%. This contributed to the annual value of -$22.0 million for FY2024, which is 3961.58% up from last year.
  • As of Q3 2025, Exagen's Enterprise Value stood at -$35.7 million, which was down 6201.5% from -$30.0 million recorded in Q2 2025.
  • In the past 5 years, Exagen's Enterprise Value ranged from a high of -$11.2 million in Q1 2025 and a low of -$118.1 million during Q1 2021
  • Its 5-year average for Enterprise Value is -$55.6 million, with a median of -$36.5 million in 2023.
  • Per our database at Business Quant, Exagen's Enterprise Value plummeted by 7676.61% in 2021 and then surged by 5897.44% in 2025.
  • Quarter analysis of 5 years shows Exagen's Enterprise Value stood at -$99.4 million in 2021, then soared by 37.26% to -$62.4 million in 2022, then surged by 41.51% to -$36.5 million in 2023, then skyrocketed by 39.62% to -$22.0 million in 2024, then plummeted by 62.01% to -$35.7 million in 2025.
  • Its last three reported values are -$35.7 million in Q3 2025, -$30.0 million for Q2 2025, and -$11.2 million during Q1 2025.